|
1
|
Breyer MD, Böttinger E, Brosius FC III, et
al: AMDCC: Mouse models of diabetic nephropathy. J Am Soc Nephrol.
16:27–45. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mauer SM, Steffes MW, Ellis EN, et al:
Structural-functional relationships in diabetic nephropathy. J Clin
Invest. 74:1143–1155. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brosius FC III, Alpers CE, Bottinger EP,
Breyer MD, Coffman TM, Gurley SB, Harris RC, Kakoki M, Kretzler M,
Leiter EH, Levi M, McIndoe RA, Sharma K, Smithies O, Susztak K,
Takahashi N and Takahashi T: Animal Models of Diabetic
Complications Consortium: Mouse models of diabetic nephropathy. J
Am Soc Nephrol. 20:2503–2512. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sharma AK, Kanawat DS, Mishra A, Dhakad
PK, Sharma P, Srivastava V, Joshi S, Joshi M, Raikwar SK, Kurmi MK
and Srinivasan BP: Dual therapy of vildagliptin and telmisartan on
diabetic nephropathy in experimentally induced type 2 diabetes
mellitus rats. J Renin Angiotensin Aldosterone Syst. Feb
8–2013.(Epub ahead of print).
|
|
5
|
Moresco RN, Sangoi MB, De Carvalho JA,
Tatsch E and Bochi GV: Diabetic nephropathy: traditional to
proteomic markers. Clin Chim Acta. 421:17–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Goh SY, Jasik M and Cooper ME: Agents in
development for the treatment of diabetic nephropathy. Expert Opin
Emerg Drugs. 13:447–463. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Inagi R, Yamamoto Y, Nangaku M, Usuda N,
Okamato H, Kurokawa K, van Ypersele de Strihou C, Yamamoto H and
Miyata T: A severe diabetic nephropathy model with early
development of nodule-like lesions induced by megsin overexpression
in RAGE/iNOS transgenic mice. Diabetes. 55:356–366. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Endo K, Saiki A, Yamaguchi T, Sakuma K,
Sasaki H, Ban N, Kawana H, Nagayama D, Nagumo A, Ohira M, Oyama T,
Murano T, Miyashita Y, Yamamura S, Suzuki Y, Shirai K and Tatsuno
I: Probucol suppresses initiation of chronic hemodialysis therapy
and renal dysfunction-related death in diabetic nephropathy
patients: Sakura Study. J Atheroscler Thromb. 20:494–502. 2013.
View Article : Google Scholar
|
|
9
|
Yuan SL, Wang XJ and Wei YQ: Anticancer
effect of tanshinone and its mechanisms. Ai Zheng. 22:1363–1366.
2003.(In Chinese).
|
|
10
|
Jang SI, Jeong SI, Kim KJ, Kim HJ, Yu HH,
Park R, Kim HM and You YO: Tanshinone IIA from Salvia
miltiorrhiza inhibits inducible nitric oxide synthase
expression and production of TNF-alpha, IL-1beta and IL-6 in
activated RAW 264.7 cells. Planta Med. 69:1057–1059.
2003.PubMed/NCBI
|
|
11
|
Wang JW and Wu JY: Tanshinone biosynthesis
in Salvia miltiorrhiza and production in plant tissue
cultures. Appl Microbiol Biotechnol. 88:437–449. 2010.
|
|
12
|
Kwak HB, Yang D, Ha H, Lee JH, Kim HN, Woo
ER, Lee S, Kim HH and Lee ZH: Tanshinone IIA inhibits osteoclast
differentiation through down-regulation of c-Fos and NFATc1. Exp
Mol Med. 38:256–264. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim SK, Jung KH and Lee BC: Protective
effect of Tanshinone IIA on the early stage of experimental
diabetic nephropathy. Biol Pharm Bull. 32:220–224. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hong HJ, Liu JC, Chen PY, Chen JJ, Chan P
and Cheng TH: Tanshinone IIA prevents doxorubicin-induced
cardiomyocyte apoptosis through Akt-dependent pathway. Int J
Cardiol. 157:174–179. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gao J, Yang G, Pi R, Li R, Wang P, Zhang
H, Le K, Chen S and Liu P: Tanshinone IIA protects neonatal rat
cardiomyocytes from adriamycin-induced apoptosis. Transl Res.
151:79–87. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Song DY, Huang QH, Zhou BR, Xu Y, Yin ZQ,
Permatasari F and Luo D: Tanshinone IIA inhibits the
dihydrotestosterone-induced secretion of lipids and activation of
sterol regulatory element binding protein-1 in HaCaT cells. Exp
Ther Med. 4:339–343. 2012.
|
|
17
|
Ishinaga H, Jono H, Lim JH, Kweon SM, Xu
H, Ha UH, Koga T, Yan C, Feng XH, Chen LF and Li JD: TGF-beta
induces p65 acetylation to enhance bacteria-induced NF-kappaB
activation. EMBO J. 26:1150–1162. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jono H, Shuto T, Xu H, Kai H, Lim DJ, Gum
JR Jr, Kim YS, Yamaoka S, Feng XH and Li JD: Transforming growth
factor-beta-Smad signaling pathway cooperates with NF-kappa B to
mediate nontypeable Haemophilus influenzae-induced MUC2
mucin transcription. J Biol Chem. 277:45547–45557. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mikami F, Lim JH, Ishinaga H, Ha UH, Gu H,
Koga T, Jono H, Kai H and Li JD: The transforming growth
factor-beta-Smad3/4 signaling pathway acts as a positive regulator
for TLR2 induction by bacteria via a dual mechanism involving
functional cooperation with NF-kappaB and MAPK phosphatase
1-dependent negative cross-talk with p38 MAPK. J Biol Chem.
281:22397–22408. 2006.
|
|
20
|
Said G: Inflammatory phenomena in diabetic
neuropathies. Journ Annu Diabetol Hotel Dieu. 251–255. 2006.(In
French).
|
|
21
|
Little AA, Edwards JL and Feldman EL:
Diabetic neuropathies. Pract Neurol. 7:82–92. 2007.
|
|
22
|
Girardi JM, Farias RE, Ferreira AP and
Raposo NR: Rosuvastatin prevents proteinuria and renal inflammation
in nitric oxide-deficient rats. Clinics (Sao Paulo). 66:1457–1462.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
24
|
Ka SM, Yeh YC, Huang XR, Chao TK, Hung YJ,
Yu CP, Lin TJ, Wu CC, Lan HY and Chen A: Kidney-targeting Smad7
gene transfer inhibits renal TGF-β/MAD homologue (SMAD) and nuclear
factor κB (NF-κB) signalling pathways, and improves diabetic
nephropathy in mice. Diabetologia. 55:509–519. 2012.PubMed/NCBI
|
|
25
|
Yamagishi S, Fukami K, Ueda S and Okuda S:
Molecular mechanisms of diabetic nephropathy and its therapeutic
intervention. Curr Drug Targets. 8:952–959. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Forbes JM, Fukami K and Cooper ME:
Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin
Endocrinol Diabetes. 115:69–84. 2007. View Article : Google Scholar
|
|
27
|
Kujubu DA, Fletcher BS, Varnum BC, Lim RW
and Herschman HR: TIS10, a phorbol ester tumor promoter-inducible
mRNA from Swiss 3T3 cells, encodes a novel prostaglandin
synthase/cyclooxygenase homologue. J Biol Chem. 266:12866–12872.
1991.
|
|
28
|
Cheng HF, Wang CJ, Moeckel GW, Zhang MZ,
McKanna JA and Harris RC: Cyclooxygenase-2 inhibitor blocks
expression of mediators of renal injury in a model of diabetes and
hypertension. Kidney Int. 62:929–939. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Owada A, Suda S and Hata T: Effect of
long-term administration of prostaglandin I(2) in incipient
diabetic nephropathy. Nephron. 92:788–796. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou X, Wang B, Zhu L and Hao S: A novel
improved therapy strategy for diabetic nephropathy: targeting AGEs.
Organogenesis. 8:18–21. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ding H, Li F, Xu M, Deng Y, Deng Q, Zhu Z,
Cheng H, Fu Z and Wang Y: The effect of inhibiting nuclear
factor-kappa B on the diabetic nephropathy. Zhonghua Nei Ke Za Zhi.
41:605–609. 2002.(In Chinese).
|
|
32
|
Miyata T, Suzuki N and van Ypersele de
Strihou C: Diabetic nephropathy: are there new and potentially
promising therapies targeting oxygen biology? Kidney Int.
84:693–702. 2013. View Article : Google Scholar
|
|
33
|
Fernández Fernández B1, Elewa U,
Sánchez-Niño MD, Rojas-Rivera JE, Martin-Cleary C, Egido J and
Ortiz A: 2012 update on diabetic kidney disease: the expanding
spectrum, novel pathogenic insights and recent clinical trials.
Minerva Med. 103:219–234. 2012.PubMed/NCBI
|
|
34
|
Kanasaki K, Taduri G and Koya D: Diabetic
nephropathy: the role of inflammation in fibroblast activation and
kidney fibrosis. Front Endocrinol (Lausanne). 4:72013.PubMed/NCBI
|
|
35
|
Shaker OG and Sadik NA: Transforming
growth factor beta 1 and monocyte chemoattractant protein-1 as
prognostic markers of diabetic nephropathy. Hum Exp Toxicol.
32:1089–1096. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hills CE and Squires PE: The role of TGF-β
and epithelial-to mesenchymal transition in diabetic nephropathy.
Cytokine Growth Factor Rev. 22:131–139. 2011.
|
|
37
|
Sharma K, Ix JH, Mathew AV, Cho M,
Pflueger A, Dunn SR, Francos B, Sharma S, Falkner B, McGowan TA,
Donohue M, Ramachandrarao S, Xu R, Fervenza FC and Kopp JB:
Pirfenidone for diabetic nephropathy. J Am Soc Nephrol.
22:1144–1151. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lan HY: Diverse roles of TGF-β/Smads in
renal fibrosis and inflammation. Int J Biol Sci. 7:1056–1067.
2011.
|
|
39
|
Choi K, Lee K, Ryu SW, Im M, Kook KH and
Choi C: Pirfenidone inhibits transforming growth factor-β1-induced
fibrogenesis by blocking nuclear translocation of Smads in human
retinal pigment epithelial cell line ARPE-19. Mol Vis.
18:1010–1020. 2012.
|
|
40
|
Meng XM, Chung AC and Lan HY: Role of the
TGF-β/BMP-7/Smad pathways in renal diseases. Clin Sci (Lond).
124:243–254. 2013.
|
|
41
|
Lan HY and Chung AC: TGF-β/Smad signaling
in kidney disease. Semin Nephrol. 32:236–243. 2012.
|
|
42
|
Liu Z, Huang XR, Chen HY, Penninger JM and
Lan HY: Loss of angiotensin-converting enzyme 2 enhances
TGF-β/Smad-mediated renal fibrosis and NF-κB-driven renal
inflammation in a mouse model of obstructive nephropathy. Lab
Invest. 92:650–661. 2012.PubMed/NCBI
|
|
43
|
Ko GJ, Kang YS, Han SY, Lee MH, Song HK,
Han KH, Kim HK, Han JY and Cha DR: Pioglitazone attenuates diabetic
nephropathy through an anti-inflammatory mechanism in type 2
diabetic rats. Nephrol Dial Transplant. 23:2750–2760. 2008.
View Article : Google Scholar : PubMed/NCBI
|
